15% Tariffs Come to U.S. Pharma in New EU Trade Action
Summary:
In a newly announced tariff arrangement between the U.S. and EU, a 15% duty on pharmaceutical imports has raised concern across the industry. While major firms may absorb the impact through U.S. operations, analysts warn of higher costs and disruption to global supply chains.
GSK and Hengrui Ink $500M Biologics Deal Across Key Therapeutic Areas
Summary:
GSK will pay $500 million to Hengrui for access to a Phase 1 COPD drug candidate and options on up to 11 additional programs in respiratory, immune, and cancer-related diseases. Hengrui will lead early development, with GSK holding rights to take over after Phase 1. The deal could total up to $12 billion if all milestones are met.
Merck Drops Key Asset from $1.9B Acquisition
Summary:
Merck has discontinued development of a mid-stage autoimmune therapy acquired via its $1.9B buyout of Pandion Therapeutics, citing limited clinical benefit. The move reflects shifting R&D priorities and a sharper focus on late-stage candidates with clearer outcomes.
Enzyme Innovation Boosts Bioconjugation Efficiency
Summary:
Researchers have developed an ATP-driven enzymatic system that enables more efficient production of protein C-terminal thioesters – key for bioconjugation in biologics manufacturing. This breakthrough could streamline design workflows for complex therapeutic proteins.
Biotech Layoff Wave Reflects Market Pressures
Summary:
The BioSpace Layoff Tracker continues to log significant workforce reductions across U.S. biotech firms. Layoffs reflect capital shortages, pipeline cuts, and strategic shifts – posing challenges for talent retention and industry confidence.
